Characterization of anti-GBM antibodies involved in Goodpasture's syndrome
(1994) In Kidney International 46(3). p.823-829- Abstract
- Characterization of anti-GBM antibodies involved in Goodpasture's syndrome. Goodpasture's syndrome is a life threatening autoimmune kidney disease. The patients have autoantibodies to the glomerular basement membrane, which are specific for the C-terminal domain of type IV collagen (NC1). The major antigen has been localized to the alpha3(IV)-chain. We have investigated sera from 44 patients with anti-NC1 antibodies. The quantity of antibodies to four different alpha(IV)-chains of type IV collagen was measured with direct ELISA. We used affinity chromatography to separate the antibodies and their specificities were studied with ELISA. The results show that about 1% of the patients total IgG are anti-NC1 antibodies and that 90% of these... (More)
- Characterization of anti-GBM antibodies involved in Goodpasture's syndrome. Goodpasture's syndrome is a life threatening autoimmune kidney disease. The patients have autoantibodies to the glomerular basement membrane, which are specific for the C-terminal domain of type IV collagen (NC1). The major antigen has been localized to the alpha3(IV)-chain. We have investigated sera from 44 patients with anti-NC1 antibodies. The quantity of antibodies to four different alpha(IV)-chains of type IV collagen was measured with direct ELISA. We used affinity chromatography to separate the antibodies and their specificities were studied with ELISA. The results show that about 1% of the patients total IgG are anti-NC1 antibodies and that 90% of these antibodies are specific for the alpha3(IV)-chain. Antibodies to the other alpha(IV)-chains were found in 80% of the patients. Furthermore, affinity purified anti-alpha3(IV) antibodies from one patient were inhibited by antibodies from the other patients, from 4 to 72%. The antibodies, from 39 of the patients, were inhibited by a monoclonal antibody against the alpha3(IV)-chain. The results indicate that patients with Goodpasture's syndrome can have antibodies to most of the alpha(IV)-chains, while the majority of anti-NC1 antibodies are restricted to the alpha3(IV)-chain. Moreover the number of epitopes seems to be limited and the majority of the antibodies from most patients are against one single epitope on the alpha3(IV)-chain. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1107773
- author
- Hellmark, Thomas LU ; Johansson, Charlott and Wieslander, Jörgen LU
- organization
- publishing date
- 1994
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Kidney International
- volume
- 46
- issue
- 3
- pages
- 823 - 829
- publisher
- Nature Publishing Group
- external identifiers
-
- pmid:7527877
- scopus:0028132838
- ISSN
- 1523-1755
- DOI
- 10.1038/ki.1994.338
- language
- English
- LU publication?
- yes
- id
- ebc2f34e-5e2d-4930-9878-e5e2387646d2 (old id 1107773)
- date added to LUP
- 2016-04-01 17:09:48
- date last changed
- 2021-02-07 04:57:09
@article{ebc2f34e-5e2d-4930-9878-e5e2387646d2, abstract = {{Characterization of anti-GBM antibodies involved in Goodpasture's syndrome. Goodpasture's syndrome is a life threatening autoimmune kidney disease. The patients have autoantibodies to the glomerular basement membrane, which are specific for the C-terminal domain of type IV collagen (NC1). The major antigen has been localized to the alpha3(IV)-chain. We have investigated sera from 44 patients with anti-NC1 antibodies. The quantity of antibodies to four different alpha(IV)-chains of type IV collagen was measured with direct ELISA. We used affinity chromatography to separate the antibodies and their specificities were studied with ELISA. The results show that about 1% of the patients total IgG are anti-NC1 antibodies and that 90% of these antibodies are specific for the alpha3(IV)-chain. Antibodies to the other alpha(IV)-chains were found in 80% of the patients. Furthermore, affinity purified anti-alpha3(IV) antibodies from one patient were inhibited by antibodies from the other patients, from 4 to 72%. The antibodies, from 39 of the patients, were inhibited by a monoclonal antibody against the alpha3(IV)-chain. The results indicate that patients with Goodpasture's syndrome can have antibodies to most of the alpha(IV)-chains, while the majority of anti-NC1 antibodies are restricted to the alpha3(IV)-chain. Moreover the number of epitopes seems to be limited and the majority of the antibodies from most patients are against one single epitope on the alpha3(IV)-chain.}}, author = {{Hellmark, Thomas and Johansson, Charlott and Wieslander, Jörgen}}, issn = {{1523-1755}}, language = {{eng}}, number = {{3}}, pages = {{823--829}}, publisher = {{Nature Publishing Group}}, series = {{Kidney International}}, title = {{Characterization of anti-GBM antibodies involved in Goodpasture's syndrome}}, url = {{http://dx.doi.org/10.1038/ki.1994.338}}, doi = {{10.1038/ki.1994.338}}, volume = {{46}}, year = {{1994}}, }